The first Oral broad spectrum anti-fungal.



NEW

Nizoral

trademark

(ketoconazole)

Superficial Fungal Infections.

NIZORAL* is a new *Oral* anti-fungal agent effective against both dermatophyte and yeast infection of the skin and scalp.

Recurrent Vaginal Candidosis.

NIZORAL* offers a simple, effective *Oral* therapy to aid patient compliance.

Systemic Fungal Infections.

NIZORAL* is a uniquely convenient and well tolerated treatment. It is also effective in prophylaxis for immuno-compromised patients.

PRESCRIBING INFORMATION: Presentation White, flat, half scored uncoated tablets marked 'JANSSEN' on the reverse. Each contains ketoconazole 200 mg. **Uses** Nizoral* is an orally active antimycotic for the treatment, in adults, of superficial and systemic mycoses including dermatophyte and yeast infection of the skin and hair, yeast infection of the mouth and G.I. tract, recurrent or chronic vaginal candidosis not responding to topical treatment. Also maintenance treatment in systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in 'at risk' patients. In children: systemic mycoses and severe local infection where previous topical treatment has failed. **Side-effects, Precautions, Contra-indications** Contra-indicated in pregnancy. For optimum absorption, Nizoral* should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H_2 blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral.* Nausea, skin rash, occasionally observed. **Dosage** *Adults:* superficial and systemic mycoses, prophylactic treatment – 200 mg once daily increased to 400 mg daily if required: vaginal candidosis – 200 mg morning and evening for 5 days. *Children:* 50 or 100 mg depending on bodyweight (approximately 3 mg/kg). **Product Licence No.** PL.0242/0083. **Basic NHS Cost** 10 tablets £4.90. 30 tablets £14.26 (correct at time of printing).

Further information is available from **Janssen Pharmaceutical Limited**, Janssen House, Chapel Street, Marlow, Bucks. SL7 1ET.

*Trademark



Presentation. Actifed is available as tablets and syrup. Each tablet contains 2.5mg triprolidine hydrochloride and 60mg pseudoephedrine hydrochloride. Each 5ml of syrup contains 1.25mg triprolidine hydrochloride and 30mg pseudoephedrine hydrochloride. **Indications** Symptomatic relief of upper respiratory congestion in the common cold, hay fever, vasomotor and allergic rhinitis, acute sinusitis, otitis barotrauma. **Dosage** Three times a day: Adults and children over 12 years: 1 tablet or 10ml. 6-12 years: 7.5ml. 1-6 years: 5ml. 3-12 months: 2.5ml. **Contra-indications** Actifed is contra-indicated in persons hypersensitive to pseudoephedrine or triprolidine and in those under treatment with MAO inhibitors and within 2 weeks of stopping such treatment. **Precautions** Although at recommended dosage pseudoephedrine has virtually no pressor effects in normotensive subjects, Actifed should be used with caution in patients with cardiovascular disorders. As with other antihistamine containing preparations, drowsiness may occur. In some patients the action of antihistamines may be potentiated by alcohol. 25 tablets. PL3/5003. 150ml. PL3/5004.

Actifed™

Pseudoephedrine Hydrochloride BP
Triprolidine Hydrochloride BP

The decongestant chosen by NASA

Further information is available on request.
Wellcome Medical Division, The Wellcome Foundation Ltd., Crewe, Cheshire

The combination of simple language and straightforward line drawings has made the

ABC OF OPHTHALMOLOGY

one of the most popular series of articles in the Medical Practice section of the British Medical Journal.

All the common problems are covered - visual defects, squints, glaucoma and cataracts - together with detailed instruction on examination, diagnosis and management.

The articles have now been collected into book form - in exactly the same format as they appeared in the BMJ - price: Inland £2.50; Overseas US$6.25 (Inland £2.00; Overseas US$5.00 for BMA members).



AVAILABLE NOW

Order your copy now
From: The Publisher,
British Medical Journal,
BMA House,
Tavistock Square,
London WC1H 9JR
or any leading bookseller



LOPRESORETIC®

metoprolol tartrate and chlorthalidone BP

FOR HYPERTENSION

Presentation Off-white, round, film-coated tablets containing 100mg metoprolol tartrate and 12.5mg chlorthalidone BP. Indications Mild and moderate hypertension. Dosage Initially two tablets in the morning, occasionally it may be beneficial to raise the dosage to three or four tablets daily given in single or divided doses. Contra-indications Atrioventricular block of second or third degree, marked bradycardia, cardiogenic shock, uncontrolled heart failure, marked renal insufficiency, lithium therapy. Side-effects Lopresoretic is well tolerated with a low incidence and severity of side-effects. However, slight gastro-intestinal discomfort, sleep disturbances, nausea, dizziness and bradycardia may occasionally occur. There have been a few reports of skin rashes and/or dry eyes associated with the use of beta-adrenoceptor blocking drugs. Usually the symptoms clear on withdrawal of treatment. Chlorthalidone may cause latent gout or latent diabetes to become manifest; a few cases of allergic skin reactions, mild anorexia, nausea, constipation and diarrhoea have been reported and, rarely, thrombocytopenia and leucopenia. Precautions Although Lopresoretic contains a selective beta-blocker caution should be observed when treating patients with chronic obstructive pulmonary disease and impaired carbohydrate metabolism. Patients with cardiac failure must be effectively digitalised. Caution in patients with renal failure, metabolic acidosis or those undergoing surgery. Cessation of therapy with a beta-blocker should be gradual. As with all drugs Lopresoretic should only be used during pregnancy if there are compelling reasons. Packs Lopresoretic (PL 0001/0085) Calendar packs of 56 tablets £7.44. Further information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.

GEIGY